At a glance
- Originator Fujisawa
- Class Neuroprotectants; Nootropics; Piperazines; Small molecules
- Mechanism of Action Serotonin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Cognition disorders; Dementia
Most Recent Events
- 03 Feb 2017 Discontinued - Phase-II for Alzheimer's disease in USA (unspecified route)
- 30 Jul 2004 Discontinued - Phase-II for Cognition disorders in Europe (unspecified route)
- 30 Jul 2004 Discontinued - Phase-II for Cognition disorders in United Kingdom (unspecified route)